Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients

Table 1 Baseline characteristics of the patients

Variable	All (n = 68)	Surgery (n = 49)	Exploration (n = 19)	P value
Age (yr)	54.3 ± 1.4	52.6 ± 1.7	58.6 ± 2.2	0.435
Gender, Male	50 (73.5%)	34 (69.4%)	16 (84.2%)	0.924
HBV infection	16 (23.5%)	13(26.5%)	3 (15.8%)	0.997
HCV infection	4 (5.9%)	2 (4.1%)	2 (10.5%)	0.314
Ascites	14 (20.6%)	1 (2.0%)	13(68.4%)	< 0.001
Tumor size(cm)	6.9 ± 0.3	6.8 ± 0.4	7.63 ± 0.5	0.495
ALT (IU/L)(median)	1.8-92.1 (26)	1.8-92.1 (24.9)	23-76.3 (32.1)	0.031
AST (IU/L) (median)	9.6-74.2 (29)	9.6-74.2 (27.3)	18.2-61.9 (31)	0.142
ALP (U/L) (median)	13.4-280.5 (82.8)	13.4-280.5 (81.4)	45.3-109.9 (85.4)	0.149
GGT (U/L) (median)	11-325.6 (42.4)	11-325.6 (41.1)	28.9-104.7 (45.8)	0.512
TBIL (mg/dL) (median)	4.2-140.0 (18)	4.2-140 (18.1)	4.2-42.6 (17.8)	0.707
CA19-9 (U/mL) (median)	21-2000 (34.5)	21-1891 (36)	22-2000 (30)	0.104
Differentiation				0.536
Poor	30 (44.1%)	20 (40.8%)	10 (40.052.6
Poor-moderate	24 (35.3%)	19 (38.8%)	5 (26.3%)
Moderate	14 (20.6%)	10 (20.4%)	4 (21.1%)
Nodal metastasis	33 (48.5%)	14 (28.6%)	19 (100.0%)	< 0.001
Tumor location				< 0.001
Left lobe	28 (41.2%)	11 (22.4%)	17 (89.5%)
Right lobe	40 (58.8%)	38 (77.6%)	2 (10.5%)
Vascular invasion	31 (45.6%)	13 (26.5%)	19 (100.0%)	< 0.001

HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Glutamic pyruvic transaminase; AST: Glutamic oxaloacetic transaminase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyltransferase; TBIL: Total bilirubin; CA19-9: Carbohydrate antigen 19-9.